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respectively. Favourable prognostic factors in univariate and 
multivariate analysis were early stage, tumour size < 4 cm (after 
adjusting for the residual disease after radiation), no pelvic 
lymph node involvement and one week gap between EBRT and 
HDR brachytherapy in three-year DFS (p = 0.001, p = 0.012, p = 
0.005, p = 0.005 respectively). The three-year OS rate was 85.7%, 
76.4%, 42%, and 33.3% for Stages I, II, III, and IVA, respectively. 
Favourable prognostic factors in univariate and multivariate 
analysis were early stage, tumour size < 4 cm, no pelvic lymph 
node involvement, one week gap between EBRT and HDR 
brachytherapy and no distant metastasis (during the follow up) 
in three-year OS (p = 0.001, p = 0.002, p = 0.002, p = 0.002, p = 
0.001 respectively). 
Conclusions: HDR brachytherapy with Co-60 remote after 
loading system was successful and it showed HDR brachytherapy 
in treating patients with carcinoma of cervix was effective after 
EBRT with acceptable rectal and bladder complications. 
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Purpose: The quality of prostate brachytherapy implant depends 
on accurate placement of seeds in their intended locations. This 
study will investigate intraoperative factors that potentially 
contribute to seed placement inaccuracy in prostate 
brachytherapy. 
Methods and Materials: Intraoperative video images of the 
brachytherapist’s hands motion and needle insertions during the 
implant procedure were acquired for analysis. Using video 
analysis software, maximum and average insertion velocities 
were measured. Number of needle insertion attempts and the 
use of brachytherapist’s other hand to manipulate the lateral 
needle movements were also recorded. Magnitude of seed 
displacements from their target location were measured in 
ultrasound images acquired following completion of each implant 
using VariSeed treatment planning software. 
Results: Fifteen patients agreed to undergo this study. 1619 
iodine-125 seeds were inserted using 357 needles. 1197 seeds 
were confidently identified in the ultrasound images and 
included in the analysis. Mean overall displacement was 0.49 cm 
(0 to 2.1 cm, 95% CI = 0.48-0.52). Six hundred and fourteen seeds 
were delivered with a single pass and 583 seeds were delivered 
with > 1 passes (range 1 to 6). Mean maximum velocity was 12.17 
cms-1 (range 4 to 28 cms-1) and mean average velocity was 4.77 
cms-1 (range 0.4 to 17.4 cms-1). Seven hundred and forty-seven 
seeds were delivered with manipulation of the needle by the 
brachytherapist’s other hand. Generalized linear model (GLM) 
was used to determine the factors contributing to seed 
displacement and found that maximum insertion velocities < 12 
ms-1 was associated with a decrease in seed displacements by 
0.049cm compared to maximum speed of > 12 cms-1 (95%CI:-
0.09;-0.01, p = 0.0121). Other evaluated factors did not show any 
no statistically significant correlation with seed displacement: 
average speed (95%CI:-0.05;0.02, p = 0.4947), lateral 
manipulation of needle (95%CI:-0.04;0.04, p = 0.9264) and 
number of needle passes (95%CI:-0.02;0.01, p = 0.8907). 
Conclusions: This study identified that needles inserted with 
lower maximum velocities were associated with less seed 
displacement. Lateral manipulation of needle, number of passes 
and average speed did not show statistically significant 
correlation with the magnitude of seed displacement. 
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Purpose: Interstitial brachytherapy (ISBT) implantation has 
advantages over standard intracavitary techniques in locally-
advanced gynecological malignancies. The insertion of implanted 
catheters directly into tumour tissue enables higher radiation 
dose conformality and normal tissue sparing. Nevertheless, this 
procedure can be associated with pain and discomfort because 
of its invasiveness. The goal of this study is to assess pain and 
opioid use by patients implanted with a perineal ISBT applicator 
for treatment with brachytherapy. 
Methods and Materials:  Thirty-nine patients treated with high-
dose rate ISBT using a perineal template from September 2014 
to January 2016 were included in a prospective registry trial. 
Median age was 65 (range 23-88) and the cohort included 13 
cervical cancers patients, 11 primary vaginal cancers, 11 
recurrent endometrial cancers, one vulvar cancer and three 
palliative treatments. Patient characteristics (age, obesity, 
diabetes, use of anti-depressants/anxiolytics) and technical ISBT 
implantation data (number of needles, depth of implantation and 
pelvic organ intrusion) were collected. Quantity of opioid use 
(morphine-oral-equivalent-dose (MoED) per day) and maximum 
pain scores (0-10) at rest or with movement were evaluated. 
Paired t-test was used for opioid comparison between first and 
second implantations. Regression linear analysis was used to 
identify independent predictors of opioid use. 
Results: The majority of patients (34) were initially treated with 
a course of external beam radiation therapy with a median dose 
of 45 Gy to the pelvis. Twenty-two patients had a single ISBT 
implantation while 17 had a second implantation, one week 
later. The median number of needles used for each implant was 
17 (8-26) and a median of three (2-5) fractions of ISBT treatments 
were delivered. Mean MOeD use per day was statistically higher 
for the second (55 mg versus 81 mg) procedure as compared to 
the first insertion (p < 0.05). Maximum pain score at rest or 
movement was also higher after the second implantation (5/5 
versus 7/6). Age (continuous variable) and numbers of implanted 
catheter needles (dichotomized by median- 17 or less versus > 
17) were found to be significant predictors of opioid use for the
first procedure. Depth of catheter insertion and pelvic organ 
intrusion were not correlated to opioid use or pain score. 
Conclusions: Interstitial brachytherapy patients require 
adequate analgesia with opioids after applicator insertion and 
inpatient stay. The second ISBT implantation is associated with 
greater opioid consumption and higher median pain scores 
(moderate versus moderate to severe). The number of implanted 
needles correlated with increase in opioid use, whereas age had 
an inverse correlation. 
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Purpose: Magnetic resonance (MR) is considered the gold-
standard imaging modality to guide cervical cancer 
brachytherapy (BT), however introducing this modality into a BT 
process can be challenging. The Models of Care Working Group 
within Cancer Care Ontario’s Gynaecological Community of 
Practice (GYN CoP) of the Radiation Treatment Program focused 
on developing strategies for Ontario patients to access this 
technology and expertise. The aim of this study is to identify 
current models of care for cervical cancer brachytherapy (ccBT) 
